<?xml version="1.1" encoding="utf-8"?>
<rdf:RDF xmlns:OMEXlib="http://omex-library.org/"
   xmlns:bqbiol="http://biomodels.net/biology-qualifiers/"
   xmlns:bqmodel="http://biomodels.net/model-qualifiers/"
   xmlns:dc="http://purl.org/dc/terms/"
   xmlns:foaf="http://xmlns.com/foaf/0.1/"
   xmlns:local="http://omex-library.org/NewOmex.omex/NewModel.rdf#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  <rdf:Description rdf:about="http://omex-library.org/BIOMD0000000673.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00001"/>
    <bqmodel:isDescribedBy rdf:resource="local:00002"/>
    <ns1:keyword xmlns:ns1="http://prismstandard.org/namespaces/basic/2.0/">Biomodels</ns1:keyword>
    <ns2:title xmlns:ns2="http://purl.org/dc/elements/1.1/">Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease</ns2:title>
    <ns3:thumbnail xmlns:ns3="http://www.collex.org/schema#"
       rdf:resource="http://omex-library.org/BIOMD0000000673.omex/BIOMD0000000673.png"/>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <ns4:identifier xmlns:ns4="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1007/s11095-006-9048-8"/>
    <ns5:label xmlns:ns5="http://www.w3.org/2000/01/rdf-schema#">Peter Lockwood, Wayne Ewy, David Hermann &amp; Nick Holford. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease. Pharmaceutical Research 23, 9 (2006).</ns5:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <ns6:identifier xmlns:ns6="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1007/s11095-006-9048-8"/>
    <ns7:label xmlns:ns7="http://www.w3.org/2000/01/rdf-schema#">Peter Lockwood, Wayne Ewy, David Hermann &amp; Nick Holford. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease. Pharmaceutical Research 23, 9 (2006).</ns7:label>
  </rdf:Description>
</rdf:RDF>

